Last reviewed · How we verify
Cisplatin-Navelbine-Radiotherapy
Cisplatin works by crosslinking DNA, causing cell death, while Navelbine inhibits microtubule formation, disrupting cell division.
Cisplatin works by crosslinking DNA, causing cell death, while Navelbine inhibits microtubule formation, disrupting cell division. Used for Non-small cell lung cancer, Small cell lung cancer, Ovarian cancer.
At a glance
| Generic name | Cisplatin-Navelbine-Radiotherapy |
|---|---|
| Sponsor | Hospices Civils de Lyon |
| Drug class | Platinum-based chemotherapy, Vinca alkaloid |
| Target | DNA, Tubulin |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Cisplatin is a platinum-based chemotherapy drug that forms platinum-DNA adducts, leading to DNA damage and apoptosis. Navelbine, also known as vinorelbine, is a vinca alkaloid that binds to tubulin, preventing microtubule formation and thereby inhibiting cell division. This combination therapy is used to treat various types of cancer.
Approved indications
- Non-small cell lung cancer, Small cell lung cancer, Ovarian cancer
Common side effects
- Nausea
- Vomiting
- Neutropenia
- Anemia
- Thrombocytopenia
Key clinical trials
- Atovaquone With Radical ChemorADIotherapy in Locally Advanced NSCLC (PHASE1)
- Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC (PHASE2)
- Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing (PHASE2)
- Combination Chemotherapy With or Without Surgery & Chemoradiotherapy in Patients With Malignant Pleural Mesothelioma (PHASE2)
- Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients (PHASE2)
- To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer (PHASE3)
- A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC (PHASE2)
- Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer (NEOCRTEC308) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cisplatin-Navelbine-Radiotherapy CI brief — competitive landscape report
- Cisplatin-Navelbine-Radiotherapy updates RSS · CI watch RSS
- Hospices Civils de Lyon portfolio CI